Blocking the FGF/FGFR system as a new therapeutic strategy for c-Myc-driven aggressive B-cell non-Hodgkin lymphoma
B-cell non-Hodgkin lymphomas (B-NHL), including diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), are aggressive malignancies frequently driven by c-MYC. Despite current therapies, relapse remains common, highlighting the need for novel strategies. Our data indicate that FGF/FGFR signaling stabilizes c-MYC and that its inhibition induces c-MYC proteasomal degradation. We hypothesize that FGF/FGFR blockade may impair c-MYC-driven B-NHL growth and dissemination. Using FGF trapping and FGFR inhibitors, we will investigate the biological and molecular effects of FGF/FGFR blockade in DLBCL and BL in vitro and in vivo, assess its therapeutic efficacy alone or combined with R-CHOP, and develop novel FGF-trap molecules. This study may establish FGF/FGFR signaling as a novel therapeutic vulnerability inaggressive c-MYC-driven B-NHL
Selection process